Protara Therapeutics, Inc. (TARA)
NASDAQ:TARA
Want to see TARA full AI Analyst Report?
TARA Stock Chart & Stats
$5.44
-$0.26(-4.26%)
At close: 4:00 PM EST
$5.44
-$0.26(-4.26%)
Day’s Range― - ―
52-Week Range$2.77 - $7.82
Previous CloseN/A
Volume145.20K
Average Volume (3M)754.64K
Market Cap
$223.69M
Enterprise Value$145.38M
Total Cash (Recent Filing)$135.79M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Jul 30, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding56,204,240
10 Day Avg. Volume759,827
30 Day Avg. Volume754,638
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.62K
Enterprise Value/Ebitda-2.31
Forecast
1Y Price Target
$26.00Price Target Upside377.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and materially higher equity provide durable financial flexibility for a development-stage biotech. This reduces near-term solvency risk, supports continued R&D spending through milestone inflections, and improves bargaining power for partnerships or financings.
Clinical Efficacy (TARA-002)A 68% six-month complete response in Phase 2 materially exceeds the 41.9% benchmark, de-risking the lead program and strengthening the case for regulatory discussions, partnerships, or follow-on funding. This clinical validation is a durable value driver if replicated in confirmatory studies.
Governance And Management AlignmentBoard refreshment, auditor ratification, and amended equity incentive plans reflect governance strengthening and management-shareholder alignment. Clear governance practices and incentive structures support long-term execution, capital raises, and credibility with institutional partners.
Bears Say
No Revenue / Recurring LossesAs a clinical-stage company with essentially no revenue and persistent operating losses, Protara cannot self-fund operations. This structural lack of recurring income increases dependency on external capital and heightens execution risk if clinical programs encounter delays or failures.
Weak Cash Generation And Rising BurnConsistent negative operating and free cash flow with a meaningful increase in burn narrows runway and forces financing decisions. Over time this constrains strategic optionality, increases dilution risk, and can divert management focus from development to capital raising rather than execution.
Dilution And Financing Risk From Share ActionsDoubling authorized shares and warrant mechanics provide capital flexibility but signal structural reliance on equity financing. Repeated dilution risk can erode shareholder economics and complicate long-term value capture even if clinical programs succeed, making future returns more equity-dependent.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics, Inc.’s price range in the past 12 months?
Protara Therapeutics, Inc. lowest stock price was $2.77 and its highest was $7.82 in the past 12 months.
What is Protara Therapeutics, Inc.’s market cap?
Protara Therapeutics, Inc.’s market cap is $223.69M.
When is Protara Therapeutics, Inc.’s upcoming earnings report date?
Protara Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Protara Therapeutics, Inc.’s earnings last quarter?
Protara Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.369 by $0.059.
Is Protara Therapeutics, Inc. overvalued?
According to Wall Street analysts Protara Therapeutics, Inc.’s price is currently Undervalued.
Does Protara Therapeutics, Inc. pay dividends?
Protara Therapeutics, Inc. does not currently pay dividends.
What is Protara Therapeutics, Inc.’s EPS estimate?
Protara Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Protara Therapeutics, Inc. have?
Protara Therapeutics, Inc. has 56,204,240 shares outstanding.
What happened to Protara Therapeutics, Inc.’s price movement after its last earnings report?
Protara Therapeutics, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.369. Following the earnings report the stock price went up 0.971%.
Which hedge fund is a major shareholder of Protara Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (377.94% Upside)
$26.00 (377.94% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 903.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.55%
12-Months-Change
Fundamentals
Return on Equity
-38.70%
Trailing 12-Months
Asset Growth
13.86%
Trailing 12-Months
Company Description
Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
TARA Stock 12 Month Forecast
Average Price Target
$26.00
▲(377.94% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Ownership Overview
3.04% Insiders
6.29% Mutual Funds
35.76% Other Institutional Investors
46.28% Public Companies and Individual Investors
Options Prices
Currently, No data available
---